<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01200160</url>
  </required_header>
  <id_info>
    <org_study_id>P12-055</org_study_id>
    <nct_id>NCT01200160</nct_id>
  </id_info>
  <brief_title>Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America</brief_title>
  <official_title>Post-Marketing Observational Study on the Effectiveness and Safety of Niaspan® in the Treatment of Lipid Abnormalities in Latin America</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>QUASY</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      Post-Marketing Observational study of Niaspan® tablet in accordance with each country
      regulations. This study will be conducted in a prospective, single-arm, multi-center format.
      As this study is observational in nature, the follow-up of subject's is not prescriptive in
      nature and is according to the judgment of the physician (investigator in the course of
      treatment for each patient), within the period of observation of 12 months. This includes an
      enrollment period of 6 months in which each subject will be observed for approximately 6
      months. Examinations, diagnostic measures, findings and observations performed as per usual
      medical practice during the observation period will be recorded on Case Report Forms (CRFs)
      by the investigator or site staffs according to the protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Post-Marketing Observational study (PMOS) of Niaspan® tablet in accordance with
      each country regulations. This study will be conducted in a prospective, single-arm,
      multi-center format. As this study is observational in nature, the follow-up of subject's is
      not prescriptive in nature and is according to the judgment of the physician (investigator in
      the course of treatment for each patient), within the period of 12 months. This includes an
      enrollment period of 6 months and a treatment duration in which each subject will be observed
      for approximately 6 months. Examinations, diagnostic measures, findings and observations
      performed as per usual medical practice during the observation period will be recorded on
      CRFs by the investigator or site staffs according to the protocol.

      Prior to enrollment in the study, each subject will be required to give their written
      informed consent to participate in the study. Written informed consent will include a
      statement authorizing the use and/or disclosure of their personal and/or health data. The
      subject will be assured that patient confidentiality will be maintained at all times
      according to the local regulations, and that data that might identify the patient will not be
      collected

      For patient's consenting to participate in this PMOS study and meeting all of the inclusion
      and none of the exclusion criteria, at the initial visit or baseline as well at subsequent
      visits if appropriate , their demographic, medical history, physical examination, vital sign,
      flushing/adverse event assessments, concomitant medication information, Niaspan dose
      change/compliance, and lab testing will be documented as per standard medical practice in
      each country, although not in a protocolized manner.

      If Niaspan® treatment is discontinued, subjects will be followed for another 1 month for any
      adverse event.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of Niaspan</measure>
    <time_frame>24 weeks regarding baseline visit (visit1)</time_frame>
    <description>Increasing serum HDL-C (high-density lipoprotein - cholesterol) levels.
Calculated change in different variables (Difference percent for HDL, LDL, Non-HDL and Triglycerides) was obtained using the expression:
percent.change=((final.visit.variable-baseline.variable.))/(baseline.variable))*100 Then percent change is calculated at 24 weeks regarding baseline for different variables.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate Changes Induced by Niaspan at the Completion of the Study Against Base Line Values</measure>
    <time_frame>every 4 to 8 weeks for 24 weeks</time_frame>
    <description>Evaluation of changes in non-HDL-C (non-high-density lipoproteins-cholesterol) lipids, LDL- C (low-density lipoproteins-cholesterol), total cholesterol and triglycerides (including in subjects with high triglycerides ≥ 200 mg/dL), and the impact on the Framingham score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Flushing Events</measure>
    <time_frame>every 4 weeks for 24 weeks</time_frame>
    <description>evaluate occurrence of such events over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Safety and Tolerability of Niaspan</measure>
    <time_frame>every 4 weeks for 24 weeks</time_frame>
    <description>Evaluate overall safety of Niaspan through evaluation of adverse events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">128</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Lipid abnormalities</arm_group_label>
    <description>Niacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin</intervention_name>
    <arm_group_label>Lipid abnormalities</arm_group_label>
    <other_name>Niaspan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male and female subject &gt;18 years-old

          -  Subjects with primary hyperlipidemia or mixed dyslipidemia with elevated levels of
             total cholesterol,, LDL-C (low-density lipoprotein-cholesterol), triglycerides and/or
             decreased levels of HDL-C (high-density lipoprotein-cholesterol) (&lt; 40 mg/dL) and has
             demonstrated an inadequate response to a lipid-restricted diet and other
             non-pharmacologic measures alone such as exercise

          -  Subject has demonstrated persistent dyslipidemic values and/or inadequate response or
             intolerance to other pharmacologic therapies such as statins, fibrates, resins, etc.

          -  Female subjects with reproductive potential must use an approved contraceptive method
             (intrauterine device (IUD), birth control pills or barrier device) during and for 3
             months after discontinuation of study treatment.

        Exclusion Criteria

          -  Subject has been treated with any other investigational product in the last 30 days
             before the day of the screening visit

          -  Subject exhibits signs of acute illness with clinically relevant findings in the
             pre-study examination

          -  Subject has known hypersensitivity to niacin or any component of Niaspan®

          -  Subject has significant or unexplained hepatic and/or renal dysfunction

          -  Subject has active peptic ulcer disease

          -  Subject exhibits active arterial bleeding

          -  Subject is pregnant or lactating

          -  The mental condition of the subject renders him/her unable to understand the nature,
             scope, and possible consequences of the study

          -  Subject is unlikely to comply with the protocol, e.g., uncooperative attitude,
             inability to return for follow-up visits, and unlikelihood of completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique C Morales Villegas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Investigación Cardiometabólica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48183</name>
      <address>
        <city>Cali</city>
        <zip>101-102</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48182</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42108</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20129</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42110</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20234</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42103</name>
      <address>
        <city>Guadalajara, Jalisco</city>
        <zip>44657</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42105</name>
      <address>
        <city>Metepec, Estado de Mexico</city>
        <zip>52140</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42102</name>
      <address>
        <city>Mexico City DF</city>
        <zip>03920</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42107</name>
      <address>
        <city>Mexico City DF</city>
        <zip>06359</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42109</name>
      <address>
        <city>Mexico City DF</city>
        <zip>11560</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42106</name>
      <address>
        <city>Mexico City DF</city>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 26348</name>
      <address>
        <city>Mexico D.F.</city>
        <zip>C.P. 11650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42104</name>
      <address>
        <city>Tijuana, Baja California Norte</city>
        <zip>11650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42112</name>
      <address>
        <city>Tijuana, Baja California Norte</city>
        <zip>22420</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42111</name>
      <address>
        <city>Tuxtla Gutierrez, Chiapas</city>
        <zip>29000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42114</name>
      <address>
        <city>Tuxtla Gutierrez, Chiapas</city>
        <zip>29030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42113</name>
      <address>
        <city>Zacatecas</city>
        <zip>98608</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42115</name>
      <address>
        <city>Zapopan, Jalisco</city>
        <zip>45200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44202</name>
      <address>
        <city>Bolivar</city>
        <zip>8050</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 26350</name>
      <address>
        <city>Caracas</city>
        <zip>1010</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44206</name>
      <address>
        <city>Caracas</city>
        <zip>1010</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44203</name>
      <address>
        <city>Caracas</city>
        <zip>1060</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44204</name>
      <address>
        <city>Estado Carabobo</city>
        <zip>2001</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2010</study_first_submitted>
  <study_first_submitted_qc>September 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <results_first_submitted>April 29, 2013</results_first_submitted>
  <results_first_submitted_qc>May 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2014</results_first_posted>
  <last_update_submitted>May 15, 2014</last_update_submitted>
  <last_update_submitted_qc>May 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low-Density Lipoprotein Cholesterol</keyword>
  <keyword>Hypertriglyceridemia</keyword>
  <keyword>Latin America</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Sedentary Lifestyle</keyword>
  <keyword>High-Density Lipoprotein Cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lipid Abnormalities</title>
          <description>No comparison groups for this observational study. Patients receive only one type of formulation, then drug exposure was the same for all patients.
This study was conducted in a prospective, single-arm, multi-center format. As this study was observational in nature, the follow-up of subject’s was not prescriptive in nature and was according to the judgment of the investigator, within the period of observation set forth in the protocol.
Typically, Niaspan is titrated in the following manner: After Week 8, titrate to patient response and tolerance. If response to 1000 mg daily is inadequate increase dose to 1500 mg daily; may subsequently increase dose to 2000 mg daily. Ideally, Niaspan should not be increased more than 500 mg in a 4-week period and daily doses above 2000 mg are not recommended. It is expected that women may respond at lower doses than men. However, consult with the approved label for titration recommendation in the particular country.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-To-Treat (ITT) population defined as all enrolled subjects who received at least one dose of study medication</population>
      <group_list>
        <group group_id="B1">
          <title>Lipid Abnormalities</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>There were 128 recruited patients, however for one patient information about birth date is missing, then age is not possible to be calculated. Then descriptive data for “age” is for 127 patients.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venezuela</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness of Niaspan</title>
        <description>Increasing serum HDL-C (high-density lipoprotein - cholesterol) levels.
Calculated change in different variables (Difference percent for HDL, LDL, Non-HDL and Triglycerides) was obtained using the expression:
percent.change=((final.visit.variable-baseline.variable.))/(baseline.variable))*100 Then percent change is calculated at 24 weeks regarding baseline for different variables.</description>
        <time_frame>24 weeks regarding baseline visit (visit1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HDL-Cholesterol</title>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness of Niaspan</title>
          <description>Increasing serum HDL-C (high-density lipoprotein - cholesterol) levels.
Calculated change in different variables (Difference percent for HDL, LDL, Non-HDL and Triglycerides) was obtained using the expression:
percent.change=((final.visit.variable-baseline.variable.))/(baseline.variable))*100 Then percent change is calculated at 24 weeks regarding baseline for different variables.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9755" spread="7.56248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Changes Induced by Niaspan at the Completion of the Study Against Base Line Values</title>
        <description>Evaluation of changes in non-HDL-C (non-high-density lipoproteins-cholesterol) lipids, LDL- C (low-density lipoproteins-cholesterol), total cholesterol and triglycerides (including in subjects with high triglycerides ≥ 200 mg/dL), and the impact on the Framingham score</description>
        <time_frame>every 4 to 8 weeks for 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Flushing Events</title>
        <description>evaluate occurrence of such events over time</description>
        <time_frame>every 4 weeks for 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Safety and Tolerability of Niaspan</title>
        <description>Evaluate overall safety of Niaspan through evaluation of adverse events</description>
        <time_frame>every 4 weeks for 24 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lipid Abnormalities</title>
          <description>Those with the condition and exposed to the study drug</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="35" subjects_affected="31" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>An agreement is in place that includes a clause of keeping Abbott´s information confidential and that any publication would be performed under agreement with Abbott.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Expected sample size was not achieved due to supply issues with the new formulation in Mexico and the local decision in Colombia to cancel marketing the product in the country.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Carlos A Gonzalez MD, PhD</name_or_title>
      <organization>Abbott Laboratories de México</organization>
      <phone>(5255) 5809- ext 7576</phone>
      <email>carlos.gonzalez@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

